Trusted Resource for Clinical Trials, Protocols & Progress
Protocol amendments are modifications made to a clinical trial protocol after the trial has started. In Phase 3 trials—where regulatory scrutiny, patient numbers, and operational complexity are at their highest—protocol amendments can be both common and consequential.
Click to read the full article.
In certain therapeutic areas—especially rare diseases, oncology, and life-threatening conditions—randomized controlled trials may be impractical or ethically challenging in Phase 2. In such cases, researchers may use external or historical controls to assess treatment effect without a concurrent placebo or standard-of-care arm. This tutorial explores the strategic, statistical, and regulatory aspects of using external and historical data as control arms in Phase 2 clinical trials.
Click to read the full article.
Real-World Evidence (RWE) has emerged as a powerful supplement to traditional clinical trial data, especially in Phase 4 trials. Generated from everyday patient experiences and routine care, RWE provides actionable insights that inform healthcare decisions, payer coverage, guideline development, and regulatory actions.
Click to read the full article.
Phase 3 clinical trials provide controlled and statistically powered evidence on a drug’s safety and efficacy. However, they are conducted in idealized settings with strict protocols, which may not fully reflect how the drug will perform in day-to-day clinical practice. This is where Real-World Evidence (RWE) comes into play.
Click to read the full article.
Phase 3 clinical trials are large-scale, multi-country studies requiring rapid enrollment, consistent data quality, and regulatory compliance. One of the most significant determinants of success at this stage is site selection. Choosing the right clinical trial sites globally can make the difference between on-time completion and costly delays or protocol deviations.
Click to read the full article.
Patient registries are organized systems that collect uniform data on a defined population over time. In Phase 4 clinical trials, registries offer unparalleled opportunities to track drug safety, effectiveness, adherence, and real-world outcomes in large and diverse patient populations. They serve as both standalone observational studies and data infrastructure for nested sub-studies.
Click to read the full article.
Recruiting eligible participants is one of the most critical—and challenging—components of any Phase 3 clinical trial. Delays in recruitment can derail timelines, increase costs, affect statistical power, and delay drug approvals. In large-scale Phase 3 studies, where thousands of participants across multiple countries are involved, sponsors must use data-driven patient recruitment forecasting models to ensure predictability and control.
Click to read the full article.
Once a drug is on the market, physicians may begin using it for conditions beyond its approved label—a practice known as off-label use. While common and sometimes beneficial, off-label use can introduce safety risks that were not evaluated in clinical trials. Phase 4 clinical trials are uniquely positioned to monitor, assess, and inform regulatory decisions surrounding such usage.
Click to read the full article.
Phase 1 clinical trials are the first step in evaluating a new drug’s safety and pharmacokinetics in humans. With high-risk profiles, tight timelines, and the need for immediate response to adverse events, these studies demand efficient and accurate oversight. That’s where real-time data monitoring platforms come in. These technologies allow clinical teams to track safety labs, ECGs, PK samples, and vital signs in near real-time, enabling data-driven decisions during dose escalation, sentinel review, and protocol amendments.
Click to read the full article.
As Phase 3 trials expand globally and become more patient-centric, clinical operations are increasingly leveraging digital technologies. Two pivotal innovations are electronic informed consent (eConsent) and remote electronic patient-reported outcomes (ePRO). These tools help streamline operations, improve patient compliance, and ensure higher quality data in large-scale studies.
Click to read the full article.
